The institute and the research/support organization will collaborate on development of novel therapies aimed at treating the central nervous system disorder.
An expert from the institutional review board services company advises what trends to look for in the clinical trial industry over the course of coming months.
Cullinan Oncology has formed a strategic partnership with the Icahn School of Medicine at Mount Sinai to research and develop targeted therapies for cancer.
A leader from the artificial intelligence insights specialist talks discusses how the effective use of advanced analytics can lead to a number of benefits.
The oncology center’s Marie-Josée and Henry R. Kravis Cancer Ecosystems Project is intended to elevate the next generation of preclinical cancer research.
This month’s announcements include new hires, promotions, acquisitions, and other events from Saama, Javara, Firma, GlaxoSmithKline, and other companies.
During OSP’s exclusive February 23 webinar Rare and Orphan Diseases, leading expertswill lend their unique experience and expertise to the important topic.
On World Cancer Day, the Union for International Cancer Control is launching a three-year campaign with the goal to improve cancer care around the globe.
The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.
A representative from IQVIA discusses the particulars of the US agency’s new draft document and shares what it might mean for clinical trial data evaluation.
The CRO's work with La Jolla Institute for Immunology, centered on a unique mouse model, is intended to increase understanding of how the COVID-19 virus operates.
This month’s list of new technology, partnerships, and other announcements includes items from ObvioHealth, Datavant, HumanFirst, and other industry players.
The pharmaceutical company reports studies have demonstrated the main protease inhibitor of Paxlovid maintains in vitro efficiency against the variant.
The researchers, in studying how polyps morph into colorectal cancer, have set a path for improved surveillance of the disease, harnessing precision medicine.
According to the company’s 12th Annual Pharmaceutical Innovation Report, pharmaceutical R&D return on investment has climbed to its highest peak since 2014.
Performance Cell Manufacturing, a CDMO with a focus on manufacturing cell therapies, has been acquired by Great Point Partners and will now operate under the name Cellipont Bioservices.
A leader from the company discusses challenges in control labs and shares how a new solution aims to clear some key obstacles to greater effectiveness.
The collaboration will center on development of unique data sets, which could be used in helping promote better understanding of aspects of human health.
Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually.
This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
Clover Biopharmaceuticals, a clinical-stage biotech developing novel vaccines and biologic therapeutic candidates, has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
An AI expert discusses progress in the field, gaps in understanding, and how predictive modeling and other advanced analytical tools could be put to use.
A forward-looking report from company experts includes a breakdown of the top trends to watch for in pharmaceutical development and in healthcare overall.
It has been a pleasure for the OSP team to connect with a long list of fascinating industry minds and share the stories; here are a few of our favorites.
This month’s collaborations, tech partnerships, new facilities, and other happenings includes news from Flywheel, Medable, Veeva, and other organizations.
A leader from the R&D tech provider discusses the obstacles faced by drug development professionals in recent months, and ways they rose to the occasion.
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
The healthcare company has gifted $1m to form a scholarship fund for students headed toward careers in clinical research, with the aim of increasing diversity.
A leader from the advanced data and artificial intelligence specialist suggests ways to advance data collection through new tools, techniques, and thinking.
Sited in Pennsylvania, the excipients specialist’s new facility reportedly will work toward advancing drug delivery research and boosting speed to market.
According to a leader from Cytoreason, AI isn’t necessarily the best or only tool suited to discover new and novel therapies—it might take a human touch.
This month’s announcements of awards, expansions, name changes, hires, and other news includes items from CPhI, Almac Group, ICON, and other organizations.
The biotech firm has presented data from a study that could offer hope to patients with Parkinson’s, Gaucher, Alzheimer’s and other neurodegenerative conditions.
A leader from Sema4, the health intelligence company, explains how progress in genetic testing has helped advance breast cancer detection and prevention.
A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
This month’s launches, expanded facilities, partnerships, and other news includes items from Veeva, Hovione, Florence, Medidata, and other notable firms.
During our November 17 webinar Patient-centric solutions, a group of professionals representing a range of perspectives will share ideas and innovations.
The group is collaborating with AbbVie, Janssen, Novartis, Pfizer, and UCB to help advance nocturnal scratch as a digital endpoint for atopic dermatitis.
The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.
A leader from the language and tech solutions firm explains how multilingual support can improve patient recruitment and other aspects of clinical trials.
The advocacy group is joining with the Rare Disease Diversity Coalition on an initiative to identify and overcome challenges faced by minority patients.
An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.
The University of California at Irvine and the data firm will work on solutions that help integrate health data for both clinical trials and patient care.
According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.
The company has deployed with several healthcare firms, emerged from stealth, named a chief commercial officer, and landed investors backing the technology.
The conference (with online and in-person content) is slated to gather professionals for deep conversations and lively collaboration on important topics.
A leader from the pharmaceutical firm talks about some of the most impactful technologies and shares a number of notable advancements made by the company.
The US agency plans to use the software firm’s Lighthouse technology to improve understanding of COVID-19 and other conditions in long-term care facilities.
